Phase I Clinical Trial to Evaluate the Safety and Explore the Immunogenicity of a Candidate PCV13 in Healthy People Aged 2 Months (Minimum 6 Weeks) and Above
Latest Information Update: 22 Nov 2022
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors BravoVax
- 07 Nov 2022 New trial record
- 03 Nov 2022 Status changed from not yet recruiting to recruiting.